Hepatocellular carcinoma
Conditions
Interventions
Neoadjuvant hepatic arterial chemoembolization combined with hepatic arterial perfusion chemotherapy in the surgical group:Hepatic arterial chemoembolization combined with hepatic arterial perfusion c
Surgery alone group:Direct surgical treatment
Sponsors
Beijing Tsinghua Changgung Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The research subjects understand the content and significance of the study and obtain written informed consent. 2. Gender is not limited, age >=18 years old, <=75 years old; 3. Eastern Cooperative Oncology Group (ECOG) score of 0–1; 4. Liver function Child-Pugh grade A/B; 5. Clinical diagnosis of HCC or pathological diagnosis of HCC by percutaneous liver biopsy; 6. Single hepatocellular carcinoma that meets the stage Ib of liver cancer in China; 7. Based on imaging evaluation and surgical planning, the lesion is adjacent to major vasculature structures (portal vein, hepatic vein, and inferior vena cava), resulting in narrow-margin hepatectomy (resection margin < 1cm); 8. Refer to the "Expert Consensus on the Evaluation of Liver Reserve Function Before Hepatectomy" (2011 edition) to ensure that there is sufficient functional liver volume left after surgery.
Exclusion criteria
Exclusion criteria: 1. No previous anti-tumor therapy; 2. Pathological types other than HCC; 3. The distance of the tumor from the large blood vessel cannot be determined; 4. Complications of severe cirrhosis; 5. History of other malignant tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival of 1 year after surgery;Postoperative pathological evaluation of MVI;Radical surgery completion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective remission rate;Pathological remission; | — |
Countries
China
Contacts
Public ContactYang Shizhong
Beijing Tsinghua Changgung Hospital
Outcome results
None listed